Race to find better Pre-Surgery treatment for aggressive breast cancer
NCT ID NCT04138719
Summary
This study is testing which of two chemotherapy drug combinations works better to shrink tumors before surgery for triple-negative breast cancer, a more aggressive type. About 520 women will receive either nab-paclitaxel with carboplatin or nab-paclitaxel with epirubicin. The main goal is to see which combination helps more patients achieve a complete response (no detectable cancer cells) at surgery and has fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.